Michael E. Wechsler, MD

Michael Wechsler, MD, is a fellowship-trained pulmonologist who specializes in asthma, eosinophilic lung diseases, EGPA, and idiopathic hypereosinophilic syndrome at National Jewish Health.

Articles by Michael E. Wechsler, MD

Depemokimab Cuts Asthma Exacerbation Risk 46%: Michael Wechsler, MD

BySabrina McCrear,Michael E. Wechsler, MD

October 2nd 2026

Michael Wechsler, MD, of National Jewish Health, discusses how twice yearly depemokimab reduces exacerbation risk in patients with T2 asthma.

ATS 2026 Highlighted Collaboration and Innovation in Pulmonary Medicine

BySabrina McCrear,Njira L. Lugogo, MD, MS,Mark Metersky, MD,Jerry A. Krishnan, MD, PhD,Yet Khor, MD, PhD,Michael E. Wechsler, MD

May 27th 2026

ATS 2026 showcased new pulmonary therapies, clinical trials, and cross-specialty collaboration to improve patient care.

Michael Wechsler, MD, MMSc, discussed how tezepelumab may address multiple severe asthma outcomes simultaneously.

Tezepelumab Showed Broad Benefit Across Asthma Outcomes: Michael Wechsler, MD, MMSc

BySabrina McCrear,Michael E. Wechsler, MD

May 19th 2026

SUNRISE data showed tezepelumab improved asthma outcomes while reducing steroid dependence in severe asthma.

SUNRISE Data Support Steroid Reduction in Severe Asthma: Michael Wechsler, MD, MMSc

BySabrina McCrear,Michael E. Wechsler, MD

May 19th 2026

SUNRISE trial data showed tezepelumab reduced oral steroid use while maintaining asthma control in severe asthma.

Discussing the COSTS of Asthma: Controlling Outcomes, Symptoms, and Treatment Strategies

ByDonald A. Bukstein, MD,Craig A. Jones, MD,Dennis K. Ledford, MD,Peter Smith, MD,Michael E. Wechsler, MD,Frank L. Urbano, MD, FACP

October 17th 2005

Latest Updated Articles

Discussing the COSTS of Asthma: Controlling Outcomes, Symptoms, and Treatment Strategies
October 17th 2005

Michael E. Wechsler, MD

Articles by Michael E. Wechsler, MD

Depemokimab Cuts Asthma Exacerbation Risk 46%: Michael Wechsler, MD

ATS 2026 Highlighted Collaboration and Innovation in Pulmonary Medicine

Tezepelumab Showed Broad Benefit Across Asthma Outcomes: Michael Wechsler, MD, MMSc

SUNRISE Data Support Steroid Reduction in Severe Asthma: Michael Wechsler, MD, MMSc

Discussing the COSTS of Asthma: Controlling Outcomes, Symptoms, and Treatment Strategies

Latest Updated Articles

Trending on AJMC

Lung Cancer Screening Lags for People With HIV as Eligibility Triples

VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine

Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D

CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs

Experts Highlight PMOS Diagnostic, Care Gaps Amid Recent Name Change